Xeris Biopharma Holdings Inc. Stock
Xeris Biopharma Holdings Inc. took a tumble today and lost -€0.210 (-3.370%).
Xeris Biopharma Holdings Inc. is currently one of the favorites of our community with 12 Buy predictions and no Sell predictions.
With a target price of 7 € there is a slightly positive potential of 16.96% for Xeris Biopharma Holdings Inc. compared to the current price of 5.99 €.
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
B****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | -3.370% | -7.639% | -3.155% | 86.914% | -5.226% | 434.757% | 39.836% |
| Ardelyx Inc. | 0.790% | -3.658% | 33.712% | 24.981% | 34.039% | 150.580% | 4.078% |
| Evolus Inc | -1.990% | -1.456% | -31.186% | -70.147% | -25.505% | -55.138% | -23.684% |
| Champions Oncology Inc | 13.640% | -4.348% | -6.780% | -50.000% | -5.172% | 50.273% | -40.217% |
Comments
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $18.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat